Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced its bitXbio ...

Evofem Biosciences (NASDAQ:EVFM) just reported results for the second quarter of 2024. The company did not report any EPS for the quarter. The company reported revenue of $4.16 million.

Evofem CEO Saundra Pelletier, whose base salary in 2021 was $812,083, has agreed to a 40% reduction in her salary. The other remaining members of the executive team will receive 20% less than the ...

Evofem Biosciences, the buzzy but controversial women’s health startup that spent the past year trying to stay afloat, has finally found a buyer.. The San Diego company, which makes the ...

Evofem Biosciences now trades at around 80 cents a share, after hitting a high of $1.57 in early July. (The stock was below 40 cents before the Supreme Court ruling.) ...

--Evofem Biosciences, Inc. today announced that the United States Patent and Trademark Office issued to the Company a Notice of Allowance for patent application 17/ 028,838, ...

Evofem's commercial team relaunched SOLOSEC in November 2024, and promotes the product alongside PHEXXI to OB/GYNs in the U.S. The Company is entering global markets through strategic ...

Evofem also plans to potentially expand its women’s health portfolio with tests developed by Aditxt's subsidiary Pearsanta, including a Mitomic ovarian test for early detection of ovarian cancer.

SAN DIEGO, June 11, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCPK: EVFM) today announced that a study of SOLOSEC® (secnidazole) 2 g oral granules for recurrent ...